Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review.

Genet Med · 2022 · PMC7614235 · PMID 35575786

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

There may be significant effects on cost-effectiveness depending on when and where in the clinical pathway the sample to create the PRS would be obtained, which genotypes would be assessed, how the results would be interpreted, and how findings would be communicated.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.